# A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

> **NCT04706923** · PHASE2 · RECRUITING · sponsor: **SymBio Pharmaceuticals** · enrollment: 52 (estimated)

## Conditions studied

- Adenovirus Infections
- Cytomegalovirus Infection

## Interventions

- **DRUG:** BCV

## Key facts

- **NCT ID:** NCT04706923
- **Lead sponsor:** SymBio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-16
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04706923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04706923, "A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04706923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*